Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands - Scorecard - MDSpire

Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands

  • By

  • Thomas Otten

  • Mirjam Knol

  • Lard Montesano Montessori

  • Pieter de Boer

  • Anneke Steens

  • February 10, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationInfants (0-5 years) and adolescents (15-24 years) - confirm age ranges with current guidelines.
Care Setting

Key Highlights

  • highlight_3

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider vaccination schedules of 2 + 1 for infants and 1 + 1 for adolescents based on updated incidence data.
    • Evaluate cost-effectiveness with recent data on IMD-B incidence and vaccine effectiveness.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Vaccination may prevent severe outcomes but requires careful consideration of cost-effectiveness and potential side effects.

        Clinical Best Practices

        • best_practice_1

        References

        Original Source(s)

        Evaluating the Clinical Outcomes and Economic Viability of Meningococcal B Vaccination for Infants and Adolescents in the Netherlands

        • by Thomas Otten, Mirjam Knol, Lard Montesano Montessori, Pieter de Boer, Anneke Steens

        • February 10, 2026

        Related Content

        AAE Revises Dental Trauma Guidance

        Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

        Utility and usability testing of the FrESH (free from E-Cigarettes and smoking for health) web application: A qualitative study

        Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report